Page 5 - What Is Lung News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from What is lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In What Is Lung Today - Breaking & Trending Today

New Phase III data support the benefit of Roche's Tecentriq in early-stage lung cancer

New Phase III data support the benefit of Roche's Tecentriq in early-stage lung cancer
dkoding.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dkoding.in Daily Mail and Mail on Sunday newspapers.

United States , Nathalie Meetz , Levi Garraway , Patrick Barth , Karsten Kleine , World Health Organization , Drug Administration , Head Of Global Product Development , Roche Group , Virtual Congress , Pharmaceuticals Industry , Roche Group Media Relations , European Society For Medical Oncology , American Cancer Society , Priority Review , Real Time Oncology Review , European Society , Medical Oncology , Chief Medical Officer , Global Product , International Association , Lung Cancer , Presidential Symposium , Programmed Death , World Health Organization Model Lists , Essential Medicines ,

F. Hoffmann-La Roche Ltd: Roche's Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

(0)
Tecentriq
significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study
Tecentriq
This approval marks
Tecentriq s
fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU
Basel, 5 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression , with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer, said Levi Garraway, M.D., Ph.D., Roche s Chief Medical Officer and Head of Global Product Development. Tecentriq monotherapy has been shown to improve overall survival in peop ....

United States , Nathalie Meetz , Jon Kaspar Bayard , Levi Garraway , Daniel Grotzky , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Loren Kalm , Lisa Tuomi , Patrick Barth , Karsten Kleine , World Health Organization , European Commission , Pharmaceuticals Industry , Head Of Global Product Development , Roche Group Media Relations , American Cancer Society , Chief Medical Officer , Global Product , World Conference , Lung Cancer , Programmed Death , World Health Organization Model Lists ,

F. Hoffmann-La Roche Ltd: Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

F. Hoffmann-La Roche Ltd: Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Nathalie Meetz , Levi Garraway , Daniel Grotzky , Jon Kaspar Bayard , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Lisa Tuomi , Loren Kalm , Patrick Barth , Karsten Kleine , European Commission , World Health Organization , Head Of Global Product Development , European Medicines Agency , Roche Group , Pharmaceuticals Industry , Committee For Medicinal Products Human Use , Roche Group Media Relations , American Cancer Society , Medicinal Products , Human Use , Chief Medical Officer ,